INDINOL FORTO AND EGALLOHIT IN THE TREATMENT OF CONDYLOMA ACUMINATE AND GIANT CONDYLOMA

Abstract

Genital papilloma virus is one of the commonest sexually transmitted disease. Its treatment is still under development and relapses are frequent. The article presents the results of the study of indolecarbinol (Indinol Forto) for the prevention of recurrent genital warts in 75 patients with genital or anal condyloma acuminata, BuschkeLowenstein tumor and bowenoid papulosis, after photodynamic therapy (PDT), cryodestruction, electrocoagulation or Mardil Selen application. Seven patients with Buschke-Lowenstein tumor underwent PDT with subsequent application of Egallohit gel on the lesions. Indolecarbinol 400 mg daily was prescribed for 3 months in combination with alpha2b-interferon (Viferon) 1 million IU daily during 1–3 months. No recurrences were observed during follow-up (mean follow-up duration was 3.9±2.7 years, from 5 months to 9 years). In patients with BuschkeLowenstein tumor, PDT with subsequent Egallohit application resulted in the formation of thin and cosmetically acceptable zones of atrophic scars. The article includes three case reports of patients with Buschke-Lowenstein tumor.

Keywords

• genital warts
• buschke-lowenstein tumor
• indolecarbinol
• egallohit